Answers are grounded in this paper and cite their sources.
Our data suggest a novel, promising combination therapy using IRE and allogenic NK cell immunotherapy. Larger clinical trials are required to confirm these conclusions.
No takes yet. Share an insight, caveat, or question.
Yang et al. (2018) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: